齊泊騰坦
外觀
齊泊騰坦 | |
---|---|
IUPAC名 N-(3-Methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide | |
別名 | ZD4054 賽博特坦 |
識別 | |
CAS號 | 186497-07-4 |
PubChem | 9910224 |
ChemSpider | 8085875 |
SMILES |
|
InChI |
|
InChIKey | FJHHZXWJVIEFGJ-UHFFFAOYAL |
IUPHAR配體 | 3539 |
性質 | |
化學式 | C19H16N6O4S |
摩爾質量 | 424.43 g·mol−1 |
若非註明,所有數據均出自標準狀態(25 ℃,100 kPa)下。 |
齊泊騰坦(INN:Zibotentan,開發代號:ZD4054)是阿斯利康正在開發的一種實驗性抗癌候選藥物。[1]它是一種內皮素受體拮抗劑。[2]
它未能通過針對前列腺癌的III期臨床試驗,[3]但計劃進行其他試驗。[4]齊泊騰坦加歐洲紫杉醇的耐受性已經過評估。[5]
齊泊騰坦還在臨床試驗中進行了研究,用於治療乳腺癌、結直腸癌、非小細胞肺癌、卵巢癌、硬皮病相關腎病、[6]骨轉移和心力衰竭。[7]
參考資料
[編輯]- ^ James and Growcott. Drugs of the Future. 2009.
- ^ Tomkinson H, Kemp J, Oliver S, Swaisland H, Taboada M, Morris T. Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies. BMC Clin Pharmacol. 2011, 11: 3. PMC 3070638 . PMID 21414193. doi:10.1186/1472-6904-11-3.
- ^ AZ's zibotentan flunks late-stage prostate cancer trial - FierceBiotech. www.fiercebiotech.com. [16 April 2018]. (原始內容存檔於2016-03-03).
- ^ Pfizer, AstraZeneca, and Actelion Separately Report Phase III Trial Failures - GEN. GEN. [16 April 2018]. (原始內容存檔於2018-04-17).
- ^ Trump DL, Payne H, Miller K, et al. Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. Prostate. September 2011, 71 (12): 1264–75. PMID 21271613. doi:10.1002/pros.21342.
- ^ A Phase II, Single Centre, Randomised, Placebo-controlled, 3-part Trial to Assess the Safety, Tolerability and Efficacy of Zibotentan in Patients With Renal Disease Secondary to Scleroderma - AdisInsight. adisinsight.springer.com. [16 April 2018]. (原始內容存檔於2023-06-22).
- ^ Zibotentan - AdisInsight. adisinsight.springer.com. [16 April 2018]. (原始內容存檔於2023-06-25).
外部連結
[編輯]- Zibotentan (頁面存檔備份,存於網際網路檔案館)